NCT02038309

Brief Summary

Study of persistent platelet reactivity during acute coronary syndrome. Patients are included at admission to the hospital. Platelet aggregation is evaluated by platelet function testing after blood sampling during hospitalization. No changes in treatment is planned.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
106

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 12, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 16, 2014

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

July 25, 2024

Status Verified

January 1, 2014

Enrollment Period

11 months

First QC Date

January 12, 2014

Last Update Submit

July 24, 2024

Conditions

Acute Coronary Syndrome

Keywords

Acute coronary syndromepersistent platelet reactivity

Outcome Measures

Primary Outcomes (1)

  • maximum aggregation intensity

    Light transmission aggregometry following exposition to arachidonic acid 0.5mg/ml during the acute phase (day2-day 5)

    day 2

Secondary Outcomes (2)

  • Maximum aggregation intensity

    Day 2

  • Maximum aggregation intensity

    Chronic phase (day 30 to day 60)

Other Outcomes (2)

  • Major cardiovascular and cerebrovascular events (MACCE)

    one year

  • microvascular resistance index

    Day 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Acute coronary syndrome

You may qualify if:

  • acute coronary syndrome with elevation in troponin

You may not qualify if:

  • anticoagulant treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Cardiology - Lariboisiere Hospital

Paris, 75010, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples

MeSH Terms

Conditions

Acute Coronary Syndrome

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Patrick Henry, MD-PhD

    Department of Cardiology - Lariboisiere Hospital - APHP

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Department of Cardiology

Study Record Dates

First Submitted

January 12, 2014

First Posted

January 16, 2014

Study Start

January 1, 2013

Primary Completion

December 1, 2013

Study Completion

December 1, 2015

Last Updated

July 25, 2024

Record last verified: 2014-01

Locations

FR(1)